Neuronetics, Inc. (NASDAQ: STIM) Stock Competitors & Peer Comparison
See STIM's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for STIM and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| STIM | $2.25 | -5.46% | 171.1M | -5.10 | -$0.44 | N/A |
| ABT | $106.20 | +1.56% | 183.8B | 20.39 | $5.21 | +2.37% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| MDT | $96.54 | -0.59% | 123.5B | 17.46 | $5.53 | +2.96% |
| SYK | $291.86 | -6.38% | 111.9B | 21.79 | $13.39 | +1.20% |
| BSX | $41.98 | -1.66% | 60.8B | 13.54 | $3.10 | N/A |
| EW | $92.01 | -2.57% | 53.1B | 34.09 | $2.70 | N/A |
| GEHC | $76.57 | +0.99% | 34.5B | 16.76 | $4.56 | +0.19% |
| DXCM | $82.29 | +2.95% | 31.1B | 32.28 | $2.55 | N/A |
| PHG | $26.92 | -0.74% | 26.2B | 15.39 | $1.75 | +3.68% |
Stock Comparison
Abbott Laboratories (NYSE: ABT)
STIM vs ABT Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, ABT has a market cap of 183.8B. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while ABT trades at $106.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas ABT's P/E ratio is 20.39. In terms of profitability, STIM's ROE is -1.51%, compared to ABT's ROE of +0.09%. Regarding short-term risk, STIM is more volatile compared to ABT. This indicates higher risk in terms of short-term price fluctuations for STIM.Check ABT's competition here
Boston Scientific Corporation (NYSE: BSX-PA)
STIM vs BSX-PA Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, STIM's ROE is -1.51%, compared to BSX-PA's ROE of +0.14%. Regarding short-term risk, STIM is more volatile compared to BSX-PA. This indicates higher risk in terms of short-term price fluctuations for STIM.Check BSX-PA's competition here
Medtronic Plc (NYSE: MDT)
STIM vs MDT Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, MDT has a market cap of 123.5B. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while MDT trades at $96.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas MDT's P/E ratio is 17.46. In terms of profitability, STIM's ROE is -1.51%, compared to MDT's ROE of +0.11%. Regarding short-term risk, STIM is more volatile compared to MDT. This indicates higher risk in terms of short-term price fluctuations for STIM.Check MDT's competition here
Stryker Corporation (NYSE: SYK)
STIM vs SYK Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, SYK has a market cap of 111.9B. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while SYK trades at $291.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas SYK's P/E ratio is 21.79. In terms of profitability, STIM's ROE is -1.51%, compared to SYK's ROE of +0.16%. Regarding short-term risk, STIM is more volatile compared to SYK. This indicates higher risk in terms of short-term price fluctuations for STIM.Check SYK's competition here
Boston Scientific Corporation (NYSE: BSX)
STIM vs BSX Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, BSX has a market cap of 60.8B. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while BSX trades at $41.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas BSX's P/E ratio is 13.54. In terms of profitability, STIM's ROE is -1.51%, compared to BSX's ROE of +0.14%. Regarding short-term risk, STIM is more volatile compared to BSX. This indicates higher risk in terms of short-term price fluctuations for STIM.Check BSX's competition here
Edwards Lifesciences Corporation (NYSE: EW)
STIM vs EW Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, EW has a market cap of 53.1B. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while EW trades at $92.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas EW's P/E ratio is 34.09. In terms of profitability, STIM's ROE is -1.51%, compared to EW's ROE of +0.10%. Regarding short-term risk, STIM is more volatile compared to EW. This indicates higher risk in terms of short-term price fluctuations for STIM.Check EW's competition here
GE HealthCare Technologies Inc. (NASDAQ: GEHC)
STIM vs GEHC Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, GEHC has a market cap of 34.5B. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while GEHC trades at $76.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas GEHC's P/E ratio is 16.76. In terms of profitability, STIM's ROE is -1.51%, compared to GEHC's ROE of +0.16%. Regarding short-term risk, STIM is more volatile compared to GEHC. This indicates higher risk in terms of short-term price fluctuations for STIM.Check GEHC's competition here
DexCom, Inc. (NASDAQ: DXCM)
STIM vs DXCM Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, DXCM has a market cap of 31.1B. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while DXCM trades at $82.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas DXCM's P/E ratio is 32.28. In terms of profitability, STIM's ROE is -1.51%, compared to DXCM's ROE of +0.37%. Regarding short-term risk, STIM is more volatile compared to DXCM. This indicates higher risk in terms of short-term price fluctuations for STIM.Check DXCM's competition here
Koninklijke Philips N.V. (NYSE: PHG)
STIM vs PHG Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, PHG has a market cap of 26.2B. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while PHG trades at $26.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas PHG's P/E ratio is 15.39. In terms of profitability, STIM's ROE is -1.51%, compared to PHG's ROE of +0.10%. Regarding short-term risk, STIM is more volatile compared to PHG. This indicates higher risk in terms of short-term price fluctuations for STIM.Check PHG's competition here
Zimmer Biomet Holdings, Inc. (NYSE: ZBH)
STIM vs ZBH Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, ZBH has a market cap of 18B. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while ZBH trades at $94.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas ZBH's P/E ratio is 11.15. In terms of profitability, STIM's ROE is -1.51%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, STIM is more volatile compared to ZBH. This indicates higher risk in terms of short-term price fluctuations for STIM.Check ZBH's competition here
Abiomed, Inc. (NASDAQ: ABMD)
STIM vs ABMD Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas ABMD's P/E ratio is 65.36. In terms of profitability, STIM's ROE is -1.51%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, STIM is more volatile compared to ABMD. This indicates higher risk in terms of short-term price fluctuations for STIM.Check ABMD's competition here
Glaukos Corporation (NYSE: GKOS)
STIM vs GKOS Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, GKOS has a market cap of 14.3B. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while GKOS trades at $237.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas GKOS's P/E ratio is -281.83. In terms of profitability, STIM's ROE is -1.51%, compared to GKOS's ROE of -0.25%. Regarding short-term risk, STIM is more volatile compared to GKOS. This indicates higher risk in terms of short-term price fluctuations for STIM.Check GKOS's competition here
Penumbra, Inc. (NYSE: PEN)
STIM vs PEN Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, PEN has a market cap of 12.6B. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while PEN trades at $318.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas PEN's P/E ratio is 83.34. In terms of profitability, STIM's ROE is -1.51%, compared to PEN's ROE of +0.10%. Regarding short-term risk, STIM is more volatile compared to PEN. This indicates higher risk in terms of short-term price fluctuations for STIM.Check PEN's competition here
ShockWave Medical, Inc. (NASDAQ: SWAV)
STIM vs SWAV Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas SWAV's P/E ratio is 78.76. In terms of profitability, STIM's ROE is -1.51%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, STIM is more volatile compared to SWAV. This indicates higher risk in terms of short-term price fluctuations for STIM.Check SWAV's competition here
Smith & Nephew plc (NYSE: SNN)
STIM vs SNN Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, SNN has a market cap of 12.4B. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while SNN trades at $29.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas SNN's P/E ratio is 20.05. In terms of profitability, STIM's ROE is -1.51%, compared to SNN's ROE of +0.12%. Regarding short-term risk, STIM is more volatile compared to SNN. This indicates higher risk in terms of short-term price fluctuations for STIM.Check SNN's competition here
Globus Medical, Inc. (NYSE: GMED)
STIM vs GMED Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, GMED has a market cap of 11.1B. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while GMED trades at $78.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas GMED's P/E ratio is 18.67. In terms of profitability, STIM's ROE is -1.51%, compared to GMED's ROE of +0.12%. Regarding short-term risk, STIM is more volatile compared to GMED. This indicates higher risk in terms of short-term price fluctuations for STIM.Check GMED's competition here
Align Technology, Inc. (NASDAQ: ALGN)
STIM vs ALGN Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, ALGN has a market cap of 10.7B. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while ALGN trades at $149.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas ALGN's P/E ratio is 13.67. In terms of profitability, STIM's ROE is -1.51%, compared to ALGN's ROE of +0.12%. Regarding short-term risk, STIM is more volatile compared to ALGN. This indicates higher risk in terms of short-term price fluctuations for STIM.Check ALGN's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO-B)
STIM vs BIO-B Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, BIO-B has a market cap of 10.5B. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while BIO-B trades at $386.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas BIO-B's P/E ratio is -68.03. In terms of profitability, STIM's ROE is -1.51%, compared to BIO-B's ROE of +0.03%. Regarding short-term risk, STIM is more volatile compared to BIO-B. This indicates higher risk in terms of short-term price fluctuations for STIM.Check BIO-B's competition here
Insulet Corp. (NASDAQ: PODD)
STIM vs PODD Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, PODD has a market cap of 10.4B. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while PODD trades at $149.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas PODD's P/E ratio is 25.51. In terms of profitability, STIM's ROE is -1.51%, compared to PODD's ROE of +0.27%. Regarding short-term risk, STIM is more volatile compared to PODD. This indicates higher risk in terms of short-term price fluctuations for STIM.Check PODD's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO)
STIM vs BIO Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, BIO has a market cap of 9.9B. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while BIO trades at $372.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas BIO's P/E ratio is 40.08. In terms of profitability, STIM's ROE is -1.51%, compared to BIO's ROE of +0.03%. Regarding short-term risk, STIM is more volatile compared to BIO. This indicates higher risk in terms of short-term price fluctuations for STIM.Check BIO's competition here
Masimo Corporation (NASDAQ: MASI)
STIM vs MASI Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while MASI trades at $179.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas MASI's P/E ratio is 44.43. In terms of profitability, STIM's ROE is -1.51%, compared to MASI's ROE of +0.09%. Regarding short-term risk, STIM is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for STIM.Check MASI's competition here
Bruker Corporation (NASDAQ: BRKRP)
STIM vs BRKRP Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, BRKRP has a market cap of 8.8B. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while BRKRP trades at $422.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas BRKRP's P/E ratio is 229.49. In terms of profitability, STIM's ROE is -1.51%, compared to BRKRP's ROE of -0.03%. Regarding short-term risk, STIM is more volatile compared to BRKRP. This indicates higher risk in terms of short-term price fluctuations for STIM.Check BRKRP's competition here
Bruker Corporation (NASDAQ: BRKR)
STIM vs BRKR Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, BRKR has a market cap of 8.7B. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while BRKR trades at $57.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas BRKR's P/E ratio is 28.69. In terms of profitability, STIM's ROE is -1.51%, compared to BRKR's ROE of -0.03%. Regarding short-term risk, STIM is more volatile compared to BRKR. This indicates higher risk in terms of short-term price fluctuations for STIM.Check BRKR's competition here
Haemonetics Corporation (NYSE: HAE)
STIM vs HAE Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, HAE has a market cap of 5.4B. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while HAE trades at $119.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas HAE's P/E ratio is 23.87. In terms of profitability, STIM's ROE is -1.51%, compared to HAE's ROE of +0.11%. Regarding short-term risk, STIM is more volatile compared to HAE. This indicates higher risk in terms of short-term price fluctuations for STIM.Check HAE's competition here
Inari Medical, Inc. (NASDAQ: NARI)
STIM vs NARI Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas NARI's P/E ratio is -59.24. In terms of profitability, STIM's ROE is -1.51%, compared to NARI's ROE of -0.00%. Regarding short-term risk, STIM is more volatile compared to NARI. This indicates higher risk in terms of short-term price fluctuations for STIM.Check NARI's competition here
LivaNova PLC (NASDAQ: LIVN)
STIM vs LIVN Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, LIVN has a market cap of 4.3B. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while LIVN trades at $78.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas LIVN's P/E ratio is 18.76. In terms of profitability, STIM's ROE is -1.51%, compared to LIVN's ROE of +0.15%. Regarding short-term risk, STIM is more volatile compared to LIVN. This indicates higher risk in terms of short-term price fluctuations for STIM.Check LIVN's competition here
Integer Holdings Corporation (NYSE: ITGR)
STIM vs ITGR Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, ITGR has a market cap of 4.3B. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while ITGR trades at $126.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas ITGR's P/E ratio is 19.94. In terms of profitability, STIM's ROE is -1.51%, compared to ITGR's ROE of +0.06%. Regarding short-term risk, STIM is more volatile compared to ITGR. This indicates higher risk in terms of short-term price fluctuations for STIM.Check ITGR's competition here
iRhythm Technologies, Inc. (NASDAQ: IRTC)
STIM vs IRTC Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, IRTC has a market cap of 4.1B. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while IRTC trades at $123.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas IRTC's P/E ratio is -287.02. In terms of profitability, STIM's ROE is -1.51%, compared to IRTC's ROE of -0.09%. Regarding short-term risk, STIM is more volatile compared to IRTC. This indicates higher risk in terms of short-term price fluctuations for STIM.Check IRTC's competition here
AxoGen, Inc. (NASDAQ: AXGN)
STIM vs AXGN Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, AXGN has a market cap of 2.9B. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while AXGN trades at $49.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas AXGN's P/E ratio is 129.92. In terms of profitability, STIM's ROE is -1.51%, compared to AXGN's ROE of -0.11%. Regarding short-term risk, STIM is more volatile compared to AXGN. This indicates higher risk in terms of short-term price fluctuations for STIM.Check AXGN's competition here
Neogen Corporation (NASDAQ: NEOG)
STIM vs NEOG Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, NEOG has a market cap of 2.6B. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while NEOG trades at $11.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas NEOG's P/E ratio is 42.21. In terms of profitability, STIM's ROE is -1.51%, compared to NEOG's ROE of -0.03%. Regarding short-term risk, STIM is more volatile compared to NEOG. This indicates higher risk in terms of short-term price fluctuations for STIM.Check NEOG's competition here
TransMedics Group, Inc. (NASDAQ: TMDX)
STIM vs TMDX Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, TMDX has a market cap of 2.3B. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while TMDX trades at $65.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas TMDX's P/E ratio is 33.49. In terms of profitability, STIM's ROE is -1.51%, compared to TMDX's ROE of +0.33%. Regarding short-term risk, STIM is more volatile compared to TMDX. This indicates higher risk in terms of short-term price fluctuations for STIM.Check TMDX's competition here
UFP Technologies, Inc. (NASDAQ: UFPT)
STIM vs UFPT Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, UFPT has a market cap of 2.2B. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while UFPT trades at $284.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas UFPT's P/E ratio is 29.03. In terms of profitability, STIM's ROE is -1.51%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, STIM is more volatile compared to UFPT. This indicates higher risk in terms of short-term price fluctuations for STIM.Check UFPT's competition here
NuVasive, Inc. (NASDAQ: NUVA)
STIM vs NUVA Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas NUVA's P/E ratio is 75.00. In terms of profitability, STIM's ROE is -1.51%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, STIM is more volatile compared to NUVA. This indicates higher risk in terms of short-term price fluctuations for STIM.Check NUVA's competition here
Inspire Medical Systems, Inc. (NYSE: INSP)
STIM vs INSP Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, INSP has a market cap of 2B. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while INSP trades at $68.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas INSP's P/E ratio is 29.97. In terms of profitability, STIM's ROE is -1.51%, compared to INSP's ROE of +0.18%. Regarding short-term risk, STIM is more volatile compared to INSP. This indicates higher risk in terms of short-term price fluctuations for STIM.Check INSP's competition here
Establishment Labs Holdings Inc. (NASDAQ: ESTA)
STIM vs ESTA Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, ESTA has a market cap of 1.9B. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while ESTA trades at $62.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas ESTA's P/E ratio is -49.52. In terms of profitability, STIM's ROE is -1.51%, compared to ESTA's ROE of -2.04%. Regarding short-term risk, STIM is less volatile compared to ESTA. This indicates lower risk in terms of short-term price fluctuations for STIM.Check ESTA's competition here
Butterfly Network, Inc. (NYSE: BFLY)
STIM vs BFLY Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, BFLY has a market cap of 1.7B. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while BFLY trades at $6.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas BFLY's P/E ratio is -26.62. In terms of profitability, STIM's ROE is -1.51%, compared to BFLY's ROE of -0.28%. Regarding short-term risk, STIM is less volatile compared to BFLY. This indicates lower risk in terms of short-term price fluctuations for STIM.Check BFLY's competition here
Novocure Ltd (NASDAQ: NVCR)
STIM vs NVCR Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, NVCR has a market cap of 1.5B. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while NVCR trades at $13.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas NVCR's P/E ratio is -10.11. In terms of profitability, STIM's ROE is -1.51%, compared to NVCR's ROE of -0.36%. Regarding short-term risk, STIM is more volatile compared to NVCR. This indicates higher risk in terms of short-term price fluctuations for STIM.Check NVCR's competition here
Tandem Diabetes Care, Inc. (NASDAQ: TNDM)
STIM vs TNDM Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, TNDM has a market cap of 1.3B. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while TNDM trades at $19.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas TNDM's P/E ratio is -20.54. In terms of profitability, STIM's ROE is -1.51%, compared to TNDM's ROE of -0.46%. Regarding short-term risk, STIM is more volatile compared to TNDM. This indicates higher risk in terms of short-term price fluctuations for STIM.Check TNDM's competition here
CONMED Corporation (NYSE: CNMD)
STIM vs CNMD Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, CNMD has a market cap of 1.3B. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while CNMD trades at $44.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas CNMD's P/E ratio is 9.74. In terms of profitability, STIM's ROE is -1.51%, compared to CNMD's ROE of +0.07%. Regarding short-term risk, STIM is more volatile compared to CNMD. This indicates higher risk in terms of short-term price fluctuations for STIM.Check CNMD's competition here
Heska Corporation (NASDAQ: HSKA)
STIM vs HSKA Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas HSKA's P/E ratio is -62.49. In terms of profitability, STIM's ROE is -1.51%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, STIM is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for STIM.Check HSKA's competition here
Avanos Medical, Inc. (NYSE: AVNS)
STIM vs AVNS Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while AVNS trades at $24.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas AVNS's P/E ratio is 27.77. In terms of profitability, STIM's ROE is -1.51%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, STIM is more volatile compared to AVNS. This indicates higher risk in terms of short-term price fluctuations for STIM.Check AVNS's competition here
Enovis Corporation (NYSE: ENOV)
STIM vs ENOV Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, ENOV has a market cap of 1.1B. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while ENOV trades at $19.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas ENOV's P/E ratio is 5.71. In terms of profitability, STIM's ROE is -1.51%, compared to ENOV's ROE of -0.68%. Regarding short-term risk, STIM is less volatile compared to ENOV. This indicates lower risk in terms of short-term price fluctuations for STIM.Check ENOV's competition here
Silk Road Medical, Inc (NASDAQ: SILK)
STIM vs SILK Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas SILK's P/E ratio is -18.96. In terms of profitability, STIM's ROE is -1.51%, compared to SILK's ROE of -0.35%. Regarding short-term risk, STIM is more volatile compared to SILK. This indicates higher risk in terms of short-term price fluctuations for STIM.Check SILK's competition here
Artivion, Inc. (NYSE: AORT)
STIM vs AORT Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, AORT has a market cap of 1.1B. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while AORT trades at $22.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas AORT's P/E ratio is 37.63. In terms of profitability, STIM's ROE is -1.51%, compared to AORT's ROE of -0.01%. Regarding short-term risk, STIM is more volatile compared to AORT. This indicates higher risk in terms of short-term price fluctuations for STIM.Check AORT's competition here
Paragon 28, Inc. (NYSE: FNA)
STIM vs FNA Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas FNA's P/E ratio is -19.83. In terms of profitability, STIM's ROE is -1.51%, compared to FNA's ROE of -0.35%. Regarding short-term risk, STIM is more volatile compared to FNA. This indicates higher risk in terms of short-term price fluctuations for STIM.Check FNA's competition here
Lumexa Imaging Holdings, Inc. Common Stock (NASDAQ: LMRI)
STIM vs LMRI Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, LMRI has a market cap of 1.1B. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while LMRI trades at $11.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas LMRI's P/E ratio is -22.20. In terms of profitability, STIM's ROE is -1.51%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, STIM is more volatile compared to LMRI. This indicates higher risk in terms of short-term price fluctuations for STIM.Check LMRI's competition here
PROCEPT BioRobotics Corporation (NASDAQ: PRCT)
STIM vs PRCT Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, PRCT has a market cap of 1.1B. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while PRCT trades at $19.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas PRCT's P/E ratio is -9.89. In terms of profitability, STIM's ROE is -1.51%, compared to PRCT's ROE of -0.31%. Regarding short-term risk, STIM is more volatile compared to PRCT. This indicates higher risk in terms of short-term price fluctuations for STIM.Check PRCT's competition here
Alphatec Holdings, Inc. (NASDAQ: ATEC)
STIM vs ATEC Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, ATEC has a market cap of 1.1B. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while ATEC trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas ATEC's P/E ratio is -117.42. In terms of profitability, STIM's ROE is -1.51%, compared to ATEC's ROE of -5.47%. Regarding short-term risk, STIM is less volatile compared to ATEC. This indicates lower risk in terms of short-term price fluctuations for STIM.Check ATEC's competition here
CeriBell, Inc. (NASDAQ: CBLL)
STIM vs CBLL Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, CBLL has a market cap of 1B. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while CBLL trades at $26.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas CBLL's P/E ratio is -15.11. In terms of profitability, STIM's ROE is -1.51%, compared to CBLL's ROE of -0.45%. Regarding short-term risk, STIM is more volatile compared to CBLL. This indicates higher risk in terms of short-term price fluctuations for STIM.Check CBLL's competition here
Integra LifeSciences Holdings Corporation (NASDAQ: IART)
STIM vs IART Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, IART has a market cap of 991.6M. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while IART trades at $12.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas IART's P/E ratio is 5.40. In terms of profitability, STIM's ROE is -1.51%, compared to IART's ROE of +0.01%. Regarding short-term risk, STIM is more volatile compared to IART. This indicates higher risk in terms of short-term price fluctuations for STIM.Check IART's competition here
IRadimed Corporation (NASDAQ: IRMD)
STIM vs IRMD Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, IRMD has a market cap of 980.5M. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while IRMD trades at $76.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas IRMD's P/E ratio is 38.53. In terms of profitability, STIM's ROE is -1.51%, compared to IRMD's ROE of +0.24%. Regarding short-term risk, STIM is more volatile compared to IRMD. This indicates higher risk in terms of short-term price fluctuations for STIM.Check IRMD's competition here
SI-BONE, Inc. (NASDAQ: SIBN)
STIM vs SIBN Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, SIBN has a market cap of 952.4M. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while SIBN trades at $21.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas SIBN's P/E ratio is -62.50. In terms of profitability, STIM's ROE is -1.51%, compared to SIBN's ROE of -0.08%. Regarding short-term risk, STIM is more volatile compared to SIBN. This indicates higher risk in terms of short-term price fluctuations for STIM.Check SIBN's competition here
Bioventus Inc. (NASDAQ: BVS)
STIM vs BVS Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, BVS has a market cap of 910.2M. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while BVS trades at $13.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas BVS's P/E ratio is 17.53. In terms of profitability, STIM's ROE is -1.51%, compared to BVS's ROE of +0.28%. Regarding short-term risk, STIM is less volatile compared to BVS. This indicates lower risk in terms of short-term price fluctuations for STIM.Check BVS's competition here
Picard Medical, Inc. (AMEX: PMI)
STIM vs PMI Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, PMI has a market cap of 857.5M. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while PMI trades at $8.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas PMI's P/E ratio is -6.96. In terms of profitability, STIM's ROE is -1.51%, compared to PMI's ROE of -9.31%. Regarding short-term risk, STIM is less volatile compared to PMI. This indicates lower risk in terms of short-term price fluctuations for STIM.Check PMI's competition here
Cardiovascular Systems, Inc. (NASDAQ: CSII)
STIM vs CSII Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas CSII's P/E ratio is -20.83. In terms of profitability, STIM's ROE is -1.51%, compared to CSII's ROE of -0.14%. Regarding short-term risk, STIM is more volatile compared to CSII. This indicates higher risk in terms of short-term price fluctuations for STIM.Check CSII's competition here
Pacific Biosciences of California, Inc. (NASDAQ: PACB)
STIM vs PACB Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, PACB has a market cap of 809.7M. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while PACB trades at $2.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas PACB's P/E ratio is -6.35. In terms of profitability, STIM's ROE is -1.51%, compared to PACB's ROE of -49.62%. Regarding short-term risk, STIM is less volatile compared to PACB. This indicates lower risk in terms of short-term price fluctuations for STIM.Check PACB's competition here
OrthoPediatrics Corp. (NASDAQ: KIDS)
STIM vs KIDS Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, KIDS has a market cap of 806.9M. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while KIDS trades at $30.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas KIDS's P/E ratio is -26.19. In terms of profitability, STIM's ROE is -1.51%, compared to KIDS's ROE of -0.10%. Regarding short-term risk, STIM is more volatile compared to KIDS. This indicates higher risk in terms of short-term price fluctuations for STIM.Check KIDS's competition here
Cytek Biosciences, Inc. (NASDAQ: CTKB)
STIM vs CTKB Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, CTKB has a market cap of 795.5M. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while CTKB trades at $6.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas CTKB's P/E ratio is -32.42. In terms of profitability, STIM's ROE is -1.51%, compared to CTKB's ROE of -0.24%. Regarding short-term risk, STIM is more volatile compared to CTKB. This indicates higher risk in terms of short-term price fluctuations for STIM.Check CTKB's competition here
AdaptHealth Corp. (NASDAQ: AHCO)
STIM vs AHCO Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, AHCO has a market cap of 792.2M. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while AHCO trades at $5.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas AHCO's P/E ratio is 11.86. In terms of profitability, STIM's ROE is -1.51%, compared to AHCO's ROE of -0.15%. Regarding short-term risk, STIM is more volatile compared to AHCO. This indicates higher risk in terms of short-term price fluctuations for STIM.Check AHCO's competition here
Varex Imaging Corporation (NASDAQ: VREX)
STIM vs VREX Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, VREX has a market cap of 782.2M. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while VREX trades at $18.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas VREX's P/E ratio is 19.39. In terms of profitability, STIM's ROE is -1.51%, compared to VREX's ROE of +0.05%. Regarding short-term risk, STIM is more volatile compared to VREX. This indicates higher risk in terms of short-term price fluctuations for STIM.Check VREX's competition here
InMode Ltd. (NASDAQ: INMD)
STIM vs INMD Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, INMD has a market cap of 760.7M. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while INMD trades at $13.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas INMD's P/E ratio is 9.18. In terms of profitability, STIM's ROE is -1.51%, compared to INMD's ROE of +0.12%. Regarding short-term risk, STIM is more volatile compared to INMD. This indicates higher risk in terms of short-term price fluctuations for STIM.Check INMD's competition here
Beta Bionics, Inc. (NASDAQ: BBNX)
STIM vs BBNX Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, BBNX has a market cap of 752.2M. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while BBNX trades at $16.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas BBNX's P/E ratio is -10.13. In terms of profitability, STIM's ROE is -1.51%, compared to BBNX's ROE of -0.27%. Regarding short-term risk, STIM is more volatile compared to BBNX. This indicates higher risk in terms of short-term price fluctuations for STIM.Check BBNX's competition here
Anteris Technologies Global Corp. (NASDAQ: AVR)
STIM vs AVR Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, AVR has a market cap of 615.5M. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while AVR trades at $6.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas AVR's P/E ratio is -3.26. In terms of profitability, STIM's ROE is -1.51%, compared to AVR's ROE of -0.78%. Regarding short-term risk, STIM is more volatile compared to AVR. This indicates higher risk in terms of short-term price fluctuations for STIM.Check AVR's competition here
Surmodics, Inc. (NASDAQ: SRDX)
STIM vs SRDX Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas SRDX's P/E ratio is -34.66. In terms of profitability, STIM's ROE is -1.51%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, STIM is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for STIM.Check SRDX's competition here
Apollo Endosurgery, Inc. (NASDAQ: APEN)
STIM vs APEN Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas APEN's P/E ratio is -9.43. In terms of profitability, STIM's ROE is -1.51%, compared to APEN's ROE of -0.85%. Regarding short-term risk, STIM is more volatile compared to APEN. This indicates higher risk in terms of short-term price fluctuations for STIM.Check APEN's competition here
ZimVie Inc. (NASDAQ: ZIMV)
STIM vs ZIMV Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, STIM's ROE is -1.51%, compared to ZIMV's ROE of -0.07%. Regarding short-term risk, STIM is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for STIM.Check ZIMV's competition here
Tactile Systems Technology, Inc. (NASDAQ: TCMD)
STIM vs TCMD Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, TCMD has a market cap of 521.9M. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while TCMD trades at $23.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas TCMD's P/E ratio is 21.33. In terms of profitability, STIM's ROE is -1.51%, compared to TCMD's ROE of +0.11%. Regarding short-term risk, STIM is more volatile compared to TCMD. This indicates higher risk in terms of short-term price fluctuations for STIM.Check TCMD's competition here
Sight Sciences, Inc. (NASDAQ: SGHT)
STIM vs SGHT Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, SGHT has a market cap of 513.4M. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while SGHT trades at $9.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas SGHT's P/E ratio is -16.64. In terms of profitability, STIM's ROE is -1.51%, compared to SGHT's ROE of -0.51%. Regarding short-term risk, STIM is more volatile compared to SGHT. This indicates higher risk in terms of short-term price fluctuations for STIM.Check SGHT's competition here
Senseonics Holdings, Inc. (NASDAQ: SENS)
STIM vs SENS Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, SENS has a market cap of 503.9M. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while SENS trades at $9.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas SENS's P/E ratio is -4.27. In terms of profitability, STIM's ROE is -1.51%, compared to SENS's ROE of -1.66%. Regarding short-term risk, STIM is more volatile compared to SENS. This indicates higher risk in terms of short-term price fluctuations for STIM.Check SENS's competition here
Delcath Systems, Inc. (NASDAQ: DCTH)
STIM vs DCTH Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, DCTH has a market cap of 487M. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while DCTH trades at $14.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas DCTH's P/E ratio is 1403.50. In terms of profitability, STIM's ROE is -1.51%, compared to DCTH's ROE of +0.00%. Regarding short-term risk, STIM is more volatile compared to DCTH. This indicates higher risk in terms of short-term price fluctuations for STIM.Check DCTH's competition here
SS Innovations International, Inc. (NASDAQ: SSII)
STIM vs SSII Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, SSII has a market cap of 471.1M. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while SSII trades at $2.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas SSII's P/E ratio is -39.17. In terms of profitability, STIM's ROE is -1.51%, compared to SSII's ROE of -0.27%. Regarding short-term risk, STIM is more volatile compared to SSII. This indicates higher risk in terms of short-term price fluctuations for STIM.Check SSII's competition here
Cerus Corporation (NASDAQ: CERS)
STIM vs CERS Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, CERS has a market cap of 460.5M. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while CERS trades at $2.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas CERS's P/E ratio is -75.91. In terms of profitability, STIM's ROE is -1.51%, compared to CERS's ROE of -0.10%. Regarding short-term risk, STIM is more volatile compared to CERS. This indicates higher risk in terms of short-term price fluctuations for STIM.Check CERS's competition here
NeuroPace, Inc. (NASDAQ: NPCE)
STIM vs NPCE Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, NPCE has a market cap of 420.8M. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while NPCE trades at $12.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas NPCE's P/E ratio is -21.51. In terms of profitability, STIM's ROE is -1.51%, compared to NPCE's ROE of -1.20%. Regarding short-term risk, STIM is more volatile compared to NPCE. This indicates higher risk in terms of short-term price fluctuations for STIM.Check NPCE's competition here
Avita Medical Inc. (NASDAQ: RCEL)
STIM vs RCEL Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, RCEL has a market cap of 389M. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while RCEL trades at $15.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas RCEL's P/E ratio is -10.87. In terms of profitability, STIM's ROE is -1.51%, compared to RCEL's ROE of +2.32%. Regarding short-term risk, STIM is more volatile compared to RCEL. This indicates higher risk in terms of short-term price fluctuations for STIM.Check RCEL's competition here
Orthofix Medical Inc. (NASDAQ: OFIX)
STIM vs OFIX Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, OFIX has a market cap of 366.8M. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while OFIX trades at $9.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas OFIX's P/E ratio is -5.91. In terms of profitability, STIM's ROE is -1.51%, compared to OFIX's ROE of -0.14%. Regarding short-term risk, STIM is less volatile compared to OFIX. This indicates lower risk in terms of short-term price fluctuations for STIM.Check OFIX's competition here
CapsoVision, Inc. (NASDAQ: CV)
STIM vs CV Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, CV has a market cap of 363.4M. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while CV trades at $6.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas CV's P/E ratio is -10.84. In terms of profitability, STIM's ROE is -1.51%, compared to CV's ROE of -1.78%. Regarding short-term risk, STIM is more volatile compared to CV. This indicates higher risk in terms of short-term price fluctuations for STIM.Check CV's competition here
ClearPoint Neuro, Inc. (NASDAQ: CLPT)
STIM vs CLPT Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, CLPT has a market cap of 326.1M. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while CLPT trades at $10.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas CLPT's P/E ratio is -9.06. In terms of profitability, STIM's ROE is -1.51%, compared to CLPT's ROE of -1.70%. Regarding short-term risk, STIM is more volatile compared to CLPT. This indicates higher risk in terms of short-term price fluctuations for STIM.Check CLPT's competition here
Semler Scientific, Inc. (NASDAQ: SMLR)
STIM vs SMLR Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas SMLR's P/E ratio is 3.92. In terms of profitability, STIM's ROE is -1.51%, compared to SMLR's ROE of +0.20%. Regarding short-term risk, STIM is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for STIM.Check SMLR's competition here
Quantum-Si incorporated (NASDAQ: QSI)
STIM vs QSI Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, QSI has a market cap of 289.5M. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while QSI trades at $1.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas QSI's P/E ratio is -3.16. In terms of profitability, STIM's ROE is -1.51%, compared to QSI's ROE of -0.47%. Regarding short-term risk, STIM is less volatile compared to QSI. This indicates lower risk in terms of short-term price fluctuations for STIM.Check QSI's competition here
Treace Medical Concepts, Inc. (NASDAQ: TMCI)
STIM vs TMCI Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, TMCI has a market cap of 287.1M. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while TMCI trades at $4.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas TMCI's P/E ratio is -4.70. In terms of profitability, STIM's ROE is -1.51%, compared to TMCI's ROE of -0.74%. Regarding short-term risk, STIM is less volatile compared to TMCI. This indicates lower risk in terms of short-term price fluctuations for STIM.Check TMCI's competition here
InfuSystem Holdings, Inc. (AMEX: INFU)
STIM vs INFU Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, INFU has a market cap of 278.8M. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while INFU trades at $14.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas INFU's P/E ratio is 34.15. In terms of profitability, STIM's ROE is -1.51%, compared to INFU's ROE of +0.15%. Regarding short-term risk, STIM is more volatile compared to INFU. This indicates higher risk in terms of short-term price fluctuations for STIM.Check INFU's competition here
Monogram Orthopaedics, Inc. (NASDAQ: MGRM)
STIM vs MGRM Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas MGRM's P/E ratio is -12.00. In terms of profitability, STIM's ROE is -1.51%, compared to MGRM's ROE of -1.17%. Regarding short-term risk, STIM is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for STIM.Check MGRM's competition here
Profound Medical Corp. (NASDAQ: PROF)
STIM vs PROF Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, PROF has a market cap of 239.7M. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while PROF trades at $6.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas PROF's P/E ratio is -6.69. In terms of profitability, STIM's ROE is -1.51%, compared to PROF's ROE of -0.56%. Regarding short-term risk, STIM is less volatile compared to PROF. This indicates lower risk in terms of short-term price fluctuations for STIM.Check PROF's competition here
TriSalus Life Sciences, Inc. (NASDAQ: TLSI)
STIM vs TLSI Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, TLSI has a market cap of 226.9M. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while TLSI trades at $3.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas TLSI's P/E ratio is -2.19. In terms of profitability, STIM's ROE is -1.51%, compared to TLSI's ROE of +2.74%. Regarding short-term risk, STIM is more volatile compared to TLSI. This indicates higher risk in terms of short-term price fluctuations for STIM.Check TLSI's competition here
Nevro Corp. (NYSE: NVRO)
STIM vs NVRO Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas NVRO's P/E ratio is -1.91. In terms of profitability, STIM's ROE is -1.51%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, STIM is more volatile compared to NVRO. This indicates higher risk in terms of short-term price fluctuations for STIM.Check NVRO's competition here
Electromed, Inc. (AMEX: ELMD)
STIM vs ELMD Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, ELMD has a market cap of 223.1M. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while ELMD trades at $27.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas ELMD's P/E ratio is 20.55. In terms of profitability, STIM's ROE is -1.51%, compared to ELMD's ROE of +0.23%. Regarding short-term risk, STIM is more volatile compared to ELMD. This indicates higher risk in terms of short-term price fluctuations for STIM.Check ELMD's competition here
RxSight, Inc. (NASDAQ: RXST)
STIM vs RXST Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, RXST has a market cap of 201.9M. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while RXST trades at $4.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas RXST's P/E ratio is -4.30. In terms of profitability, STIM's ROE is -1.51%, compared to RXST's ROE of -0.17%. Regarding short-term risk, STIM is more volatile compared to RXST. This indicates higher risk in terms of short-term price fluctuations for STIM.Check RXST's competition here
BioSig Technologies, Inc. (NASDAQ: BSGM)
STIM vs BSGM Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas BSGM's P/E ratio is -5.81. In terms of profitability, STIM's ROE is -1.51%, compared to BSGM's ROE of +6.96%. Regarding short-term risk, STIM is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for STIM.Check BSGM's competition here
Inogen, Inc. (NASDAQ: INGN)
STIM vs INGN Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, INGN has a market cap of 182.1M. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while INGN trades at $6.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas INGN's P/E ratio is -7.54. In terms of profitability, STIM's ROE is -1.51%, compared to INGN's ROE of -0.13%. Regarding short-term risk, STIM is more volatile compared to INGN. This indicates higher risk in terms of short-term price fluctuations for STIM.Check INGN's competition here
Xylo Technologies Ltd. (NASDAQ: MDGS)
STIM vs MDGS Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas MDGS's P/E ratio is -0.27. In terms of profitability, STIM's ROE is -1.51%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, STIM is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for STIM.Check MDGS's competition here
Quipt Home Medical Corp. (NASDAQ: QIPT)
STIM vs QIPT Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas QIPT's P/E ratio is -15.87. In terms of profitability, STIM's ROE is -1.51%, compared to QIPT's ROE of -0.08%. Regarding short-term risk, STIM is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for STIM.Check QIPT's competition here
EDAP TMS S.A. American Depositary Shares (NASDAQ: FOCL)
STIM vs FOCL Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, FOCL has a market cap of 158.5M. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while FOCL trades at $4.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas FOCL's P/E ratio is -4.09. In terms of profitability, STIM's ROE is -1.51%, compared to FOCL's ROE of -2.90%. Regarding short-term risk, STIM is more volatile compared to FOCL. This indicates higher risk in terms of short-term price fluctuations for STIM.Check FOCL's competition here
Quanterix Corporation (NASDAQ: QTRX)
STIM vs QTRX Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, QTRX has a market cap of 137.4M. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while QTRX trades at $2.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas QTRX's P/E ratio is -1.14. In terms of profitability, STIM's ROE is -1.51%, compared to QTRX's ROE of -0.44%. Regarding short-term risk, STIM is more volatile compared to QTRX. This indicates higher risk in terms of short-term price fluctuations for STIM.Check QTRX's competition here
Pulmonx Corporation (NASDAQ: LUNG)
STIM vs LUNG Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, LUNG has a market cap of 129.1M. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while LUNG trades at $3.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas LUNG's P/E ratio is -2.59. In terms of profitability, STIM's ROE is -1.51%, compared to LUNG's ROE of -0.98%. Regarding short-term risk, STIM is less volatile compared to LUNG. This indicates lower risk in terms of short-term price fluctuations for STIM.Check LUNG's competition here
Perspective Therapeutics, Inc. (AMEX: CATX)
STIM vs CATX Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, CATX has a market cap of 129M. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while CATX trades at $1.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas CATX's P/E ratio is -0.85. In terms of profitability, STIM's ROE is -1.51%, compared to CATX's ROE of -0.42%. Regarding short-term risk, STIM is more volatile compared to CATX. This indicates higher risk in terms of short-term price fluctuations for STIM.Check CATX's competition here
Owlet, Inc. (NYSE: OWLT)
STIM vs OWLT Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, OWLT has a market cap of 118.9M. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while OWLT trades at $4.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas OWLT's P/E ratio is -29.07. In terms of profitability, STIM's ROE is -1.51%, compared to OWLT's ROE of -0.50%. Regarding short-term risk, STIM is more volatile compared to OWLT. This indicates higher risk in terms of short-term price fluctuations for STIM.Check OWLT's competition here
iCAD, Inc. (NASDAQ: ICAD)
STIM vs ICAD Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas ICAD's P/E ratio is -20.37. In terms of profitability, STIM's ROE is -1.51%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, STIM is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for STIM.Check ICAD's competition here
Hancock Jaffe Laboratories (NASDAQ: HJLI)
STIM vs HJLI Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas HJLI's P/E ratio is N/A. In terms of profitability, STIM's ROE is -1.51%, compared to HJLI's ROE of -0.70%. Regarding short-term risk, STIM is more volatile compared to HJLI. This indicates higher risk in terms of short-term price fluctuations for STIM.Check HJLI's competition here
Asensus Surgical, Inc. (AMEX: ASXC)
STIM vs ASXC Comparison November 2026
Neuronetics, Inc. (NASDAQ: STIM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STIM stands at 171.1M. In comparison, ASXC has a market cap of 94.9M. Regarding current trading prices, STIM is priced at $2.25 on the NASDAQ, while ASXC trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STIM currently has a P/E ratio of -5.10, whereas ASXC's P/E ratio is -1.12. In terms of profitability, STIM's ROE is -1.51%, compared to ASXC's ROE of -1.18%. Regarding short-term risk, STIM is more volatile compared to ASXC. This indicates higher risk in terms of short-term price fluctuations for STIM.Check ASXC's competition here